ReVacc Biotech
ReVacc Biotech
  • Home
  • About Us
  • Pipeline
  • Technology
  • Publications
  • Newsroom
  • Investors
  • Contact
  • More
    • Home
    • About Us
    • Pipeline
    • Technology
    • Publications
    • Newsroom
    • Investors
    • Contact
  • Home
  • About Us
  • Pipeline
  • Technology
  • Publications
  • Newsroom
  • Investors
  • Contact

Year

Topic

Topic

2021

Topic

Topic

Topic

COVID-19

Title

Topic

Title

One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization

Emerging Microbes & Infections

2021

COVID-19

One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization

Pre-print on BioRxiv

2021

Influenza

RuvB-Like Protein 2 Interacts with the NS1 Protein of Influenza A Virus and Affects Apoptosis That Is Counterbalanced by Type I Interferons

Viruses

Copyright © 2020 ReVacc Biotech - All Rights Reserved.

  • About Us
  • Pipeline
  • Technology
  • Publications
  • Newsroom
  • Investors